Clinically sizeable immune-mediated hematologic adverse reactions (which includes hemolytic anemia, aplastic anemia, immune thrombocytopenic purpura) happened at an incidence of significantly less than 1% in patients who gained this drug or have been claimed with the use of other PD-1/PD-L1 blocking